TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to determine whether mesalamine is effective vs. placebo in the prevention of diverticulitis flares in a 24-months follow-up.

The primary end-point of the study is the incidence of diverticulitis flares. Will be made a clinical diagnosis of uncomplicated diverticulitis: fever, leukocytosis, abdominal pain and altered intestinal motility.


Options:
A: Arm Label: SPD476 (1.2 g); Type: EXPERIMENTAL; Interventions: Drug: SPD476 (1.2g) | Arm Label: SPD476 (2.4 g); Type: EXPERIMENTAL; Interventions: Drug: SPD476 (2.4 g) | Arm Label: SPD476 (4.8 g); Type: EXPERIMENTAL; Interventions: Drug: SPD476 (4.8 g) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SPD476 (1.2g); Assigned to Arm(s): SPD476 (1.2 g) | Intervention Type: DRUG; Name: SPD476 (2.4 g); Assigned to Arm(s): SPD476 (2.4 g) | Intervention Type: DRUG; Name: SPD476 (4.8 g); Assigned to Arm(s): SPD476 (4.8 g) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine 800 mg | Arm Label: Lactobacillus casei; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lactobacillus casei | Arm Label: Mesalazine plus Lactobacillus casei; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine plus Lactobacillus casei | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mesalazine placebo plus Lactobacillus casei placebo | Intervention Type: DRUG; Name: Mesalazine plus Lactobacillus casei; Assigned to Arm(s): Mesalazine plus Lactobacillus casei | Intervention Type: DRUG; Name: Mesalazine placebo plus Lactobacillus casei placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Mesalazine 800 mg; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Lactobacillus casei; Assigned to Arm(s): Lactobacillus casei
C: Arm Label: Antibiotic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antibiotic | Arm Label: No antibiotic; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Antibiotic; Assigned to Arm(s): Antibiotic
D: Arm Label: mesalamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: mesalamine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: mesalamine; Assigned to Arm(s): mesalamine | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 64-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and Open-label Tiotropium (18 μg o.d.) on COPD Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol Fumarate | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): 2
B: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS) | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Assigned to Arm(s): Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
C: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149, Drug: Salbutamol/albuterol | Arm Label: NVA237; Type: ACTIVE_COMPARATOR; Interventions: Drug: NVA237, Drug: Salbutamol/albuterol | Arm Label: open-label tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium, Drug: Salbutamol/albuterol | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: NVA237; Assigned to Arm(s): NVA237 | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): open-label tiotropium | Intervention Type: DRUG; Name: Salbutamol/albuterol; Assigned to Arm(s): NVA237, QVA149, open-label tiotropium
D: Arm Label: Olodaterol andTiotropium; Type: EXPERIMENTAL; Interventions: Drug: Tiotropium, Drug: Olodaterol | Arm Label: Placebo and Tiotropium; Type: OTHER; Interventions: Drug: Tiotropium, Drug: Placebo matching Olodaterol | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Placebo and Tiotropium | Intervention Type: DRUG; Name: Placebo matching Olodaterol; Assigned to Arm(s): Placebo and Tiotropium | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Olodaterol andTiotropium | Intervention Type: DRUG; Name: Olodaterol; Assigned to Arm(s): Olodaterol andTiotropium

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicener, Randomised, Double-blind, Placebo-controlled Study, to Assess the Long Term Safety of 52 Weeks Treatment With QVA149 (110 ug Indacaterol/50ug Glycopyrrolate) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The study is designed to provide long-term safety data for QVA149 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: tiotropium + olodaterol; Type: EXPERIMENTAL; Interventions: Drug: tiotropium, Drug: olodaterol | Arm Label: tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium + olodaterol | Intervention Type: DRUG; Name: olodaterol; Assigned to Arm(s): tiotropium + olodaterol | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol Fumarate | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): 2
C: Arm Label: Tiotropium + olodaterol High dose QD; Type: EXPERIMENTAL; Interventions: Drug: tiotropium + olodaterol, Device: Respimat | Arm Label: Tiotropium + olodaterol Low dose QD; Type: EXPERIMENTAL; Interventions: Drug: Tiotropium + Olodaterol, Device: Respimat | Arm Label: Tiotropium 5 mcg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium, Device: Respimat | Arm Label: Olodaterol 5 mcg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olodaterol, Device: Respimat | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Device: Respimat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium 5 mcg QD | Intervention Type: DRUG; Name: Olodaterol; Assigned to Arm(s): Olodaterol 5 mcg QD | Intervention Type: DRUG; Name: tiotropium + olodaterol; Assigned to Arm(s): Tiotropium + olodaterol High dose QD | Intervention Type: DRUG; Name: Tiotropium + Olodaterol; Assigned to Arm(s): Tiotropium + olodaterol Low dose QD | Intervention Type: DEVICE; Name: Respimat; Assigned to Arm(s): Olodaterol 5 mcg QD, Placebo QD, Tiotropium + olodaterol High dose QD, Tiotropium + olodaterol Low dose QD, Tiotropium 5 mcg QD
D: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: LUX-Lung 6: A Randomized, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Brief Summary: To investigate the efficacy and safety of BIBW 2992 compared to standard first-line chemotherapy in patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Erlotinib | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Gemcitabin, Drug: Docetaxel, Drug: Cisplatin | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Gemcitabin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): B
B: Arm Label: Arm A BIBW 2992; Type: EXPERIMENTAL; Interventions: Drug: BIBW 2992 | Arm Label: Arm B Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine+Cisplatin | Intervention Type: DRUG; Name: Gemcitabine+Cisplatin; Assigned to Arm(s): Arm B Chemotherapy | Intervention Type: DRUG; Name: BIBW 2992; Assigned to Arm(s): Arm A BIBW 2992
C: Arm Label: AZD9291+ placebo; Type: EXPERIMENTAL; Interventions: Drug: AZD9291 80 mg/40 mg + placebo, Drug: Placebo Erlotinib 150/100mg, Drug: Placebo Gefitinib 250 mg | Arm Label: Standard of Care + placebo AZD9291; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erlotinib 150/100 mg, Drug: Gefitinib 250 mg, Drug: Placebo AZD9291 80 mg/ 40 mg | Intervention Type: DRUG; Name: AZD9291 80 mg/40 mg + placebo; Assigned to Arm(s): AZD9291+ placebo | Intervention Type: DRUG; Name: Placebo Erlotinib 150/100mg; Assigned to Arm(s): AZD9291+ placebo | Intervention Type: DRUG; Name: Placebo Gefitinib 250 mg; Assigned to Arm(s): AZD9291+ placebo | Intervention Type: DRUG; Name: Erlotinib 150/100 mg; Assigned to Arm(s): Standard of Care + placebo AZD9291 | Intervention Type: DRUG; Name: Gefitinib 250 mg; Assigned to Arm(s): Standard of Care + placebo AZD9291 | Intervention Type: DRUG; Name: Placebo AZD9291 80 mg/ 40 mg; Assigned to Arm(s): Standard of Care + placebo AZD9291
D: Arm Label: Cetuximab plus chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: cetuximab + cisplatin + vinorelbine | Arm Label: Chemotherapy alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatin + vinorelbine | Intervention Type: DRUG; Name: cetuximab + cisplatin + vinorelbine; Assigned to Arm(s): Cetuximab plus chemotherapy | Intervention Type: DRUG; Name: cisplatin + vinorelbine; Assigned to Arm(s): Chemotherapy alone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Randomized Trial of the Polo-like Kinase 1 Inhibitor BI 6727 Monotherapy Versus Investigator´s Choice Chemotherapy in Ovarian Cancer Patients Resistant or Refractory to Platinum-based Cytotoxic Therapy
Brief Summary: This is an international, randomized phase II trial. The aim is to assess the efficacy and the safety of BI 6727 Versus investigator's best choice single agent cytotoxic in recurrent third and fourth lines platinum resistant/refractory ovarian cancer.

100 patients will be randomised at the study entry to receive either BI 6727 (Arm A: 50 patients) or non-platinum single agent cytotoxic (Arm B: 50 patients) Treatment will be continued until disease progression or unacceptable toxicity. Primary endpoint: disease control rate at week 24 according to Response Evaluation Criteria In Solid Tumours version 1.1.

Secondary endpoints: efficacy (progression free survival, overall survival, biological tumour response, biological progression free survival assessed by serum CA 125 according to Gynecologic Cancer Intergroup criteria, safety according to the NCI CTCAE v.3, disease symptoms control assessed by the EORTC QLQ-C30, QLQ-OV28 and individual symptoms questionnaires, pharmacokinetics of BI 6727.

Others endpoints: biomarkers and pharmacogenetics analysis (optional)


Options:
A: Arm Label: Cyclophosphamid + Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Cyclophosphamid + Pazopanib
B: Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Abraxane; Assigned to Arm(s): N/A
C: Arm Label: BI 6727; Type: EXPERIMENTAL; Interventions: Drug: BI 6727 | Arm Label: Cytotoxic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Gemcitabine, Drug: Topotecan, Drug: Pegylated liposomal doxorubicin (PLD) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: BI 6727; Assigned to Arm(s): BI 6727
D: Arm Label: DOXIL + trabectedin; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin, Drug: DOXIL, Drug: Dexamethasone | Arm Label: DOXIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: DOXIL | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): DOXIL + trabectedin | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): DOXIL, DOXIL + trabectedin | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): DOXIL + trabectedin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Parallel-Group, Randomized, 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of 50 mg Of DVS SR In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder
Brief Summary: A multicenter, 10-week study to evaluate the efficacy and safety of 50 mg of desvenlafaxine succinate sustained-release formulation (DVS SR) versus placebo in the treatment of peri- and postmenopausal women with major depressive disorder


Options:
A: Arm Label: ACT; Type: EXPERIMENTAL; Interventions: Other: Acceptance and Commitment Therapy (ACT) | Arm Label: WPI; Type: EXPERIMENTAL; Interventions: Other: workplace intervention (WPI) | Arm Label: ACT and WPI; Type: EXPERIMENTAL; Interventions: Other: Acceptance and Commitment Therapy (ACT), Other: workplace intervention (WPI) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Acceptance and Commitment Therapy (ACT); Assigned to Arm(s): ACT, ACT and WPI | Intervention Type: OTHER; Name: workplace intervention (WPI); Assigned to Arm(s): ACT and WPI, WPI
B: Arm Label: Brexpiprazole + ADT; Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole +ADT | Arm Label: Placebo + ADT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Placebo + ADT | Intervention Type: DRUG; Name: Brexpiprazole +ADT; Assigned to Arm(s): Brexpiprazole + ADT
C: Arm Label: desvenlafaxine succinate sustained-release; Type: EXPERIMENTAL; Interventions: Drug: desvenlafaxine succinate sustained-release | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: desvenlafaxine succinate sustained-release; Assigned to Arm(s): desvenlafaxine succinate sustained-release | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: IBBIS MHC; Type: EXPERIMENTAL; Interventions: Behavioral: IBBIS mental health care and standard vocational rehabilitation | Arm Label: IBBIS integrated MCH and VR; Type: EXPERIMENTAL; Interventions: Other: Integrated mental health care and vocational rehabilitation | Intervention Type: BEHAVIORAL; Name: IBBIS mental health care and standard vocational rehabilitation; Assigned to Arm(s): IBBIS MHC | Intervention Type: OTHER; Name: Integrated mental health care and vocational rehabilitation; Assigned to Arm(s): IBBIS integrated MCH and VR

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Study of 5-Fluorouracil-based Regimen With or Without Oxaliplatin as 2nd Line Treatment of Advanced or Metastatic Pancreatic Cancer in Patients Who Have Previously Received Gemcitabine-based Chemotherapy
Brief Summary: Primary Objective:

To demonstrate that the addition of oxaliplatin to 5-Fluorouracil (5-FU) and Leucovorin (LV) will improve the Progression-Free Survival (PFS). Progression is based on RECIST (Response Evaluation Criteria In Solid Tumors) criteria or death

Secondary Objective:

To evaluate other measures of tumor responses, safety, quality of life (QoL), and health utility assessment.


Options:
A: Arm Label: 5-FU & LV; Type: ACTIVE_COMPARATOR; Interventions: Drug: Leucovorin, Drug: 5-Fluorouracil | Arm Label: XELOX or modified FOLFOX-6; Type: EXPERIMENTAL; Interventions: Drug: Leucovorin, Drug: OXALIPLATIN, Drug: 5-Fluorouracil | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): 5-FU & LV, XELOX or modified FOLFOX-6 | Intervention Type: DRUG; Name: OXALIPLATIN; Assigned to Arm(s): XELOX or modified FOLFOX-6 | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): 5-FU & LV, XELOX or modified FOLFOX-6
B: Arm Label: GSK1120212 plus Gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: GSK1120212, Drug: Gemcitabine | Arm Label: Placebo plus Gemcitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine, Drug: Placebo | Intervention Type: DRUG; Name: GSK1120212; Assigned to Arm(s): GSK1120212 plus Gemcitabine | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): GSK1120212 plus Gemcitabine, Placebo plus Gemcitabine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus Gemcitabine
C: Arm Label: Gemcitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine | Arm Label: Axitinib [AG-013736] plus gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: AG-013736, Drug: Gemcitabine | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine | Intervention Type: DRUG; Name: AG-013736; Assigned to Arm(s): Axitinib [AG-013736] plus gemcitabine | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Axitinib [AG-013736] plus gemcitabine
D: Arm Label: Placebo + gemcitabine; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: gemcitabine | Arm Label: AMG 479 12 mg/kg dose + gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: AMG 479, Drug: gemcitabine | Arm Label: AMG 479 20 mg/kg + gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: AMG 479, Drug: gemcitabine | Intervention Type: DRUG; Name: AMG 479; Assigned to Arm(s): AMG 479 12 mg/kg dose + gemcitabine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + gemcitabine | Intervention Type: DRUG; Name: AMG 479; Assigned to Arm(s): AMG 479 20 mg/kg + gemcitabine | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): AMG 479 12 mg/kg dose + gemcitabine, AMG 479 20 mg/kg + gemcitabine, Placebo + gemcitabine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multi-center Observational Study With Blinded, Nested Case:Control Analyses to Evaluate the Performance of the Verinata Health Prenatal Aneuploidy Diagnostic Test
Brief Summary: The primary objective of this study is to determine the performance characteristics (sensitivity and specificity) of the Verinata Health Test to detect fetal Trisomy 21 (T21) compared to karyotype results obtained by amniocentesis or chorionic villus sampling (CVS).

Secondary objectives are to assess performance of the test to detect male gender (XY) and other less common aneuploidies (Trisomy 13 (T13), Trisomy 18 (T18), and Turner Syndrome (45, X)) compared to clinical fetal karyotype.


Options:
A: Arm Label: Case; Type: N/A; Interventions: N/A | Arm Label: Control; Type: N/A; Interventions: N/A
B: Arm Label: All-risk pregnant women; Type: N/A; Interventions: N/A
C: Arm Label: Chromosomal Abnormality; Type: N/A; Interventions: N/A | Arm Label: No Chromosomal Abnormality; Type: N/A; Interventions: N/A
D: Arm Label: Down syndrome; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sustaining Tobacco Abstinence After Incarceration
Brief Summary: The purpose of this study is to determine the extent to which an Intentional Behavioral Intervention will increase tobacco quit rates post release among incarcerated men and women.


Options:
A: Arm Label: Motivation Interviewing/CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing/CBT | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: CONcise Tapes Reviewing Obstacles to healthy Living (CONTROL) | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing/CBT; Assigned to Arm(s): Motivation Interviewing/CBT | Intervention Type: OTHER; Name: CONcise Tapes Reviewing Obstacles to healthy Living (CONTROL); Assigned to Arm(s): Control
B: Arm Label: Brief Advice; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Advice (BA) | Arm Label: Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing (MI) | Arm Label: Health Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education (HE) | Intervention Type: BEHAVIORAL; Name: Brief Advice (BA); Assigned to Arm(s): Brief Advice | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing (MI); Assigned to Arm(s): Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Health Education (HE); Assigned to Arm(s): Health Education
C: Arm Label: 1 Nix Individual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nix Individual | Arm Label: 2 Fimpa dig fri; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Fimpa dig fri | Intervention Type: BEHAVIORAL; Name: Nix Individual; Assigned to Arm(s): 1 Nix Individual | Intervention Type: BEHAVIORAL; Name: Fimpa dig fri; Assigned to Arm(s): 2 Fimpa dig fri
D: Arm Label: Standard Care; Type: EXPERIMENTAL; Interventions: Behavioral: Standard Care | Arm Label: Motivational Enhancement; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Enhancement | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard Care | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement; Assigned to Arm(s): Motivational Enhancement

Answer: A